Fintel reports that on October 7, 2024, HC Wainwright & Co. initiated coverage of DiaMedica Therapeutics (NasdaqCM:DMAC) with a Buy recommendation. Analyst Price Forecast Suggests 63.54% Upside ...

Insiders who purchased DiaMedica Therapeutics Inc. (NASDAQ:DMAC) shares in the past 12 months are unlikely to be deeply impacted by the stock's 14% decline over the past week. Reason being ...

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Diamedica Therapeutics (DMAC – Research Report). The company’s shares closed last Friday at $2.90 ...

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Diamedica Therapeutics (DMAC – Research Report). The company’s shares closed last Friday at $4.30 ...